{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:32:34Z","timestamp":1752669154448},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This study evaluated the immunogenicity and reactogenicity of a combined diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus virus-<jats:italic toggle=\"yes\">Haemophilus influenzae<\/jats:italic> type b vaccine (DTPa-HBV-IPV\/Hib) and a 10-valent pneumococcal conjugate vaccine (PHiD-CV) coadministered with a quadrivalent meningococcal conjugate vaccine (MenACWY-TT) in infants\/toddlers.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>In this open, controlled, phase III study (NCT01144663), 2095 healthy infants were randomized (1:1:1:1) into 4 groups to receive MenACWY-TT at 2, 3, 4 and 12 months of age or MenACWY-TT, MenC-CRM<jats:sub>197<\/jats:sub>, or MenC-TT at 2, 4 and 12 months of age. All participants received PHiD-CV and DTPa-HBV-IPV\/Hib at 2, 3, 4 and 12 months of age. Immunogenicity of DTPa-HBV-IPV\/Hib was evaluated in exclusive randomized subsets of 25% of participants from each group postprimary, prebooster and postbooster vaccination, whereas immunogenicity of PHiD-CV was evaluated at all time points. Reactogenicity was evaluated on the total vaccinated cohorts during 8 days after each vaccination.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>For each DTPa-HBV-IPV\/Hib antigen, \u226597.2%, \u226576.5% and \u226597.9% of participants had seropositive\/seroprotective levels 1 month postprimary vaccination, before the booster dose and 1 month postbooster, respectively. For each vaccine pneumococcal serotype, \u226574.0% of infants had antibody concentrations \u22650.35 \u03bcg\/mL at 1 month postprimary vaccination, and robust increases in antibody geometric mean concentrations were observed from prebooster to postbooster. Redness was the most frequent solicited local symptom at the DTPa-HBV-IPV\/Hib and PHiD-CV injection sites, reported after up to 47.7% and 57.0% of doses postprimary and postbooster vaccination, respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Primary and booster vaccinations of infants\/toddlers with DTPa-HBV-IPV\/Hib and PHiD-CV coadministered with MenACWY-TT were immunogenic with clinically acceptable reactogenicity profiles. These results support the coadministration of MenACWY-TT with routine childhood vaccines.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000002061","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T18:07:17Z","timestamp":1522865237000},"page":"704-714","source":"Crossref","is-referenced-by-count":4,"title":["Immunogenicity and Reactogenicity of DTPa-HBV-IPV\/Hib and PHiD-CV When Coadministered With MenACWY-TT in Infants"],"prefix":"10.1097","volume":"37","author":[{"given":"Jose Manuel","family":"Merino Arribas","sequence":"first","affiliation":[{"name":"Pediatric Department, Hospital Universitario de Burgos, Burgos, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Carmona Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Instituto Hispalense de Pediatria, Edificio Expolocal, Sevilla, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Horn","sequence":"additional","affiliation":[{"name":"Pediatric Office Dr. Horn, Schoenau, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier Maria","family":"Perez Porcuna","sequence":"additional","affiliation":[{"name":"Manlleu Primary Care Center, Manlleu Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria del Carmen","family":"Otero Reigada","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Hospital La Fe, Valencia, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Mar\u00e8s Berm\u00fadez","sequence":"additional","affiliation":[{"name":"Institut Pedi\u00e0tric Mar\u00e8s \u2013 Riera, Blanes, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Centeno Malfaz","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Rio Hortega University Hospital, Valladolid, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariano","family":"Miranda","sequence":"additional","affiliation":[{"name":"Pediatrics Department, Hospital de Antequera, Antequera, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mendez","sequence":"additional","affiliation":[{"name":"Pediatric Hospital Germans Trias i Pujol, Badalona, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miguel Angel","family":"Garcia Cabezas","sequence":"additional","affiliation":[{"name":"Hospital General Universitario de Ciudad Real, Ciudad Real, Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wittermann","family":"Christoph","sequence":"additional","affiliation":[{"name":"Study Center Weilheim, Pediatric Practice Weilheim, Weilheim i.OB, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerhard","family":"Bleckmann","sequence":"additional","affiliation":[{"name":"Private Practice Bleckmann, Baunatal, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Fischbach","sequence":"additional","affiliation":[{"name":"Private Practice Fischbach, North-Rhine, Solingen, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Devayani","family":"Kolhe","sequence":"additional","affiliation":[{"name":"Novo Nordisk India, EPIP Area, Vijayanagar, KIADB Export Promotion Industrial Area, Whitefield, Bengaluru, Karnataka, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie","family":"Van der Wielen","sequence":"additional","affiliation":[{"name":"GSK, Wavre, Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaela","family":"Baine","sequence":"additional","affiliation":[{"name":"Yaela Baine Consulting, Merion, PA."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230912","doi-asserted-by":"crossref","first-page":"e305","DOI":"10.1542\/peds.2014-2035","article-title":"Epidemiology of infant meningococcal disease in the United States, 2006-2012.","volume":"135","author":"MacNeil","year":"2015","journal-title":"Pediatrics"},{"key":"R2-20230912","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1478-7954-11-17","article-title":"Global epidemiology of invasive meningococcal disease.","volume":"11","author":"Jafri","year":"2013","journal-title":"Popul Health Metr"},{"key":"R3-20230912","first-page":"E121","article-title":"Meningococcal disease in childhood: epidemiology, clinical features and prevention.","volume":"56","author":"Bosis","year":"2015","journal-title":"J Prev Med Hyg"},{"issue":"suppl 2","key":"R5-20230912","doi-asserted-by":"crossref","first-page":"B51","DOI":"10.1016\/j.vaccine.2009.04.063","article-title":"Global epidemiology of meningococcal disease.","volume":"27","author":"Harrison","year":"2009","journal-title":"Vaccine"},{"key":"R6-20230912","doi-asserted-by":"crossref","first-page":"995","DOI":"10.4161\/hv.27739","article-title":"Review of meningococcal vaccines with updates on immunization in adults.","volume":"10","author":"Zahlanie","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R7-20230912","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1179\/2047773214Y.0000000126","article-title":"Global practices of meningococcal vaccine use and impact on invasive disease.","volume":"108","author":"Ali","year":"2014","journal-title":"Pathog Glob Health"},{"key":"R8-20230912","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.2165\/11209580-000000000-00000","article-title":"Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix\u2122).","volume":"72","author":"Croxtall","year":"2012","journal-title":"Drugs"},{"key":"R9-20230912","first-page":"85","article-title":"Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease.","volume":"7","author":"Hedari","year":"2014","journal-title":"Infect Drug Resist"},{"key":"R10-20230912","first-page":"1825","article-title":"Meningococcal quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT, Nimenrix\u2122): a review of its immunogenicity, safety, co-administration, and antibody persistence.","volume":"12","author":"Assaf-Casals","year":"2016","journal-title":"Hum Vaccin Immunother"},{"key":"R11-20230912","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/INF.0b013e31828693c5","article-title":"One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children.","volume":"32","author":"Klein","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R12-20230912","doi-asserted-by":"crossref","first-page":"866","DOI":"10.4161\/hv.20229","article-title":"Antibody persistence and immune memory 15 months after priming with an investigational tetravalent meningococcal tetanus toxoid conjugate vaccine (MenACWY-TT) in toddlers and young children.","volume":"8","author":"Knuf","year":"2012","journal-title":"Hum Vaccin Immunother"},{"key":"R13-20230912","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/j.vaccine.2009.10.064","article-title":"A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children.","volume":"28","author":"Knuf","year":"2010","journal-title":"Vaccine"},{"key":"R14-20230912","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1016\/j.vaccine.2011.03.043","article-title":"Tetravalent meningococcal serogroups A, C, W-135 and Y conjugate vaccine is well tolerated and immunogenic when co-administered with measles-mumps-rubella-varicella vaccine during the second year of life: an open, randomized controlled trial.","volume":"29","author":"Vesikari","year":"2011","journal-title":"Vaccine"},{"key":"R16-20230912","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","article-title":"Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial.","volume":"36","author":"Merino Arribas","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"R17-20230912","first-page":"337","article-title":"DTPa-HBV-IPV\/Hib vaccine (Infanrix hexa\u2122): a guide to its use in infants.","volume":"14","author":"Lyseng-Williamson","year":"2012","journal-title":"Paediatr Drugs"},{"key":"R18-20230912","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2165\/11204830-000000000-00000","article-title":"DTPa-HBV-IPV\/Hib vaccine (Infanrix hexa): a review of its use as primary and booster vaccination.","volume":"70","author":"Dhillon","year":"2010","journal-title":"Drugs"},{"key":"R19-20230912","doi-asserted-by":"crossref","first-page":"129","DOI":"10.4161\/hv.26269","article-title":"Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine; Infanrix\u2122 hexa: twelve years of experience in Italy.","volume":"10","author":"Baldo","year":"2014","journal-title":"Hum Vaccin Immunother"},{"key":"R20-20230912","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/erv.09.113","article-title":"10-valent pneumococcal nontypeable Haemophilus influenzae PD conjugate vaccine: Synflorix.","volume":"8","author":"Prymula","year":"2009","journal-title":"Expert Rev Vaccines"},{"key":"R21-20230912","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.vaccine.2015.01.081","article-title":"Choosing between 7-, 10- and 13-valent pneumococcal conjugate vaccines in childhood: a review of economic evaluations (2006-2014).","volume":"33","author":"Wu","year":"2015","journal-title":"Vaccine"},{"key":"R22-20230912","article-title":"Summary of product characteristics.","journal-title":"Synflorix"},{"key":"R23-20230912","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1128\/jcm.20.4.772-774.1984","article-title":"Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum.","volume":"20","author":"Camargo","year":"1984","journal-title":"J Clin Microbiol"},{"key":"R24-20230912","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/S0092-1157(83)80038-9","article-title":"A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera.","volume":"11","author":"Melville-Smith","year":"1983","journal-title":"J Biol Stand"},{"key":"R25-20230912","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/BF02097184","article-title":"Acellular pertussis vaccine in adults: adverse reactions and immune response.","volume":"6","author":"Granstr\u00f6m","year":"1987","journal-title":"Eur J Clin Microbiol"},{"key":"R26-20230912","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1128\/iai.31.3.1223-1231.1981","article-title":"Role of antibody to leukocytosis-promoting factor hemagglutinin and to filamentous hemagglutinin in immunity to pertussis.","volume":"31","author":"Sato","year":"1981","journal-title":"Infect Immun"},{"key":"R27-20230912","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination.","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"R29-20230912","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/infdis\/147.6.1100","article-title":"The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.","volume":"147","author":"K\u00e4yhty","year":"1983","journal-title":"J Infect Dis"},{"key":"R30-20230912","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1128\/CDLI.8.2.266-272.2001","article-title":"Pneumococcal type 22f polysaccharide absorption improves the specificity of a pneumococcal-polysaccharide enzyme-linked immunosorbent assay.","volume":"8","author":"Concepcion","year":"2001","journal-title":"Clin Diagn Lab Immunol"},{"key":"R31-20230912","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1016\/j.vaccine.2011.03.009","article-title":"An investigational tetravalent meningococcal serogroups A, C, W-135 and Y-tetanus toxoid conjugate vaccine co-administered with Infanrix\u2122 hexa is immunogenic, with an acceptable safety profile in 12-23-month-old children.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"issue":"suppl 4","key":"R32-20230912","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1097\/INF.0b013e318199f61b","article-title":"Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).","volume":"28","author":"Knuf","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R33-20230912","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/INF.0b013e3181f2da06","article-title":"Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with DTPw-HBV\/Hib and poliovirus vaccines.","volume":"30","author":"Bermal","year":"2011","journal-title":"Pediatr Infect Dis J"},{"key":"R34-20230912","doi-asserted-by":"crossref","first-page":"e206","DOI":"10.1097\/INF.0000000000001170","article-title":"Immunogenicity, safety and reactogenicity of a booster dose of the 10-valent pneumococcal nontypeable H. influenzae protein D conjugate vaccine coadministered with DTPa-IPV-Hib in Dutch children: a randomized controlled trial.","volume":"35","author":"van den Bergh","year":"2016","journal-title":"Pediatr Infect Dis J"},{"issue":"suppl 4","key":"R35-20230912","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1097\/INF.0b013e318199f609","article-title":"Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.","volume":"28","author":"Wysocki","year":"2009","journal-title":"Pediatr Infect Dis J"},{"key":"R36-20230912","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1097\/INF.0b013e3182784143","article-title":"Immunogenicity and safety of a booster dose of the 10-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine coadministered with the tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers: a randomized trial.","volume":"32","author":"Ruiz-Palacios","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"R37-20230912","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1016\/j.vaccine.2011.04.053","article-title":"Comparative effects of carrier proteins on vaccine-induced immune response.","volume":"29","author":"Knuf","year":"2011","journal-title":"Vaccine"},{"key":"R38-20230912","doi-asserted-by":"crossref","first-page":"5513","DOI":"10.1016\/j.vaccine.2010.06.026","article-title":"Glycoconjugate vaccines and immune interference: a review.","volume":"28","author":"Dagan","year":"2010","journal-title":"Vaccine"},{"key":"R39-20230912","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1128\/IAI.66.5.2093-2098.1998","article-title":"Reduced response to multiple vaccines sharing common protein epitopes that are administered simultaneously to infants.","volume":"66","author":"Dagan","year":"1998","journal-title":"Infect Immun"},{"key":"R40-20230912","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.vaccine.2004.08.030","article-title":"Booster vaccination with hexavalent DTPa-HBV-IPV\/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV\/Hib + HBV administered separately.","volume":"23","author":"Saenger","year":"2005","journal-title":"Vaccine"},{"key":"R41-20230912","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1016\/j.vaccine.2003.11.044","article-title":"Safety, reactogenicity and immunogenicity of a combined hexavalent tetanus, diphtheria, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate vaccine, for primary immunization of infants.","volume":"22","author":"Zepp","year":"2004","journal-title":"Vaccine"},{"issue":"suppl 4","key":"R42-20230912","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.1097\/INF.0b013e318199f62d","article-title":"Safety and reactogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with routine childhood vaccines.","volume":"28","author":"Chevallier","year":"2009","journal-title":"Pediatr Infect Dis J"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00018","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,12]],"date-time":"2023-09-12T22:09:07Z","timestamp":1694556547000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006454-201807000-00018"}},"subtitle":["Results of an Open, Randomized Trial"],"short-title":[],"issued":{"date-parts":[[2018,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000002061","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7]]}}}